InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Results of Next-Generation Capecitabine Analysis
Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has released information regarding its next-generation capecitabine study. According to the company, the next-generation capecitabine dosage regimen, which is a combination of PCS6422 administered with capecitabine, successfully inhibited dihydropyrimidine dehydrogenase (“DPD”), resulting in altering the metabolism of 5-fluoruracil (“5-FU”) during…